Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
IBI-354 by Innovent Biologics for Endometrial Cancer: Likelihood of Approval
IBI-354 is under clinical development by Innovent Biologics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...